10:33 AM EST - Crescita Therapeutics Inc. : Reported its financial results for the third quarter ended September 30, 2018. Revenue of $4.5 million, including $1.1 million in royalty revenue on the net sales of Pliaglis and a $1.3 million sales milestone, an increase of $1.7 million or 64.1% versus Q3-17. Adjusted EBITDA of $0.8 million, up $1.8 million versus Q3-17, an improvement of $2.1 million on a year-to-date basis. Crescita Therapeutics Inc.
shares T.CTX are trading up $0.11 at $0.54.
